To date, numerous therapeutic strategies targeting pathogenic factors in DN, including glycemic control, administration of angiotensin-converting enzyme inhibitors, and blockade of the RAAS, have been implemented and are partially effective in slowing DN progression. The gene discussed is ACE; the disease is liver dysplastic nodule.